医学
肌炎
自身抗体
免疫系统
内科学
抗体
免疫球蛋白G
骨骼肌
腓肠肌
免疫学
内分泌学
作者
Sarah Julien,Bas van der Woning,Leentje De Ceuninck,Emma Briand,Thara Jaworski,Gaëlle Roussel,Rachid Zoubaïri,Yves Allenbach,Olivier Benveniste,Laurent Drouot,Olivier Boyer
出处
期刊:Rheumatology
[Oxford University Press]
日期:2023-06-19
卷期号:62 (12): 4006-4011
被引量:6
标识
DOI:10.1093/rheumatology/kead298
摘要
Abstract Objective Immune-mediated necrotizing myopathies (IMNMs) are severe forms of myositis often associated with pathogenic anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies (aAbs). Efgartigimod is an engineered human IgG1 Fc fragment that antagonizes the neonatal Fc receptor (FcRn), thereby preventing recycling and promoting lysosomal degradation of IgG, including aAbs. We evaluated the therapeutic effects of IgG reduction by efgartigimod in a humanized murine model of IMNM. Methods Disease was induced in C5-deficient (C5def) or Rag2-deficient (Rag2–/–) mice receiving co-injections of anti-HMGCR+ IgG from an IMNM patient and human complement. C5def mice were treated in a preventive setting with s.c. injections of efgartigimod and Rag2–/– mice in a curative setting after disease was induced by anti-HMGCR+ IgG injections. Anti-HMGCR aAbs levels were monitored in mouse serum and muscle tissue. Histological analysis was performed on muscle sections. Muscle force was assessed by grip test or measurement of gastrocnemius strength upon electrostimulation. Results Administration of efgartigimod rapidly reduced total IgG levels, including the level of pathogenic anti-HMGCR aAbs, in both serum (P < 0.0001) and muscle (P < 0.001). In the preventive setting, efgartigimod prevented myofibre necrosis (P < 0.05), thus precluding loss of muscle strength (P < 0.05). In the therapeutic setting, efgartigimod prevented further necrosis and allowed muscle fibre regeneration (P < 0.05). Hence, muscle strength returned to normal (P < 0.01). Conclusion Efgartigimod reduces circulating IgG levels, including pathogenic anti-HMGCR+ IgG aAbs, in a humanized mouse model of IMNM, preventing further necrosis and allowing muscle fibre regeneration. These results support investigating the therapeutic efficacy of efgartigimod through a clinical trial in IMNM patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI